SEC Filing | EyePoint Pharmaceuticals

View:

Download DOC

Download PDF

Download XLS

Download XBRL

8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) June 26, 2024

   

EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	000-51122	26-2774444
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

480 Pleasant Street
Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

    Registrant’s Telephone Number, Including Area Code: (617) 926-5000

   

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	EYPT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On June 26, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) posted the Company’s 2024 R&D Day Presentation (the “Presentation") on its website at www.eyepointpharma.com, which Presentation included the Company’s estimated cash and investments on hand as of June 30, 2024 and certain other corporate updates. The amounts included in the Presentation were calculated prior to the completion of a review by the Company’s independent registered public accounting firm and are therefore subject to change upon completion of the Company’s quarterly report for the period ended June 30, 2024. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of June 30, 2024.

Item 8.01 Other Events.

A copy of the Presentation is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

On June 26, 2024, the Company issued a press release announcing certain clinical and regulatory developments for its lead pipeline program, DURAVYU™ (vorolanib intravitreal insert), formerly known as EYP-1901, its Durasert E™ sustained drug delivery technology and early-stage programs to be presented during the Company’s R&D Day. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description
99.1		R&D Presentation of EyePoint Pharmaceuticals, Inc. dated June 26, 2024
99.2		Press Release of EyePoint Pharmaceuticals, Inc. dated June 26, 2024
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			EYEPOINT PHARMACEUTICALS, INC.

Date:	June 26, 2024	By:	/s/ George O. Elston
			George O. Elston Executive Vice President and Chief Financial Officer

Legal Disclaimers ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for DURAVYU™ in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including DURAVYU and EYP-2301; the potential for DURAVYU as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; termination or breach of current and future license agreements; our dependence on contract research organizations and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. R&D Day Speakers: Management >30 years managing retinal diseases and is a 12-time clinical trial investigator/co investigator; he has started three companies and has published >345 ophthalmic journal articles. Previous Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston. Jay Duker, MD President and CEO >25 years of diverse financial and executive leadership in the biopharmaceutical sector with strong record of execution across strategic, operational, financial goals to drive shareholder value. He has established strong relationships across wall street and pharma/biotech resulting in transformative company-building and M&A transactions. George O. Elston EVP and CFO Extensive experience encompassing clinical practice as a retina specialist, academia and the pharmaceutical industry with a strong track record of successfully bringing novel therapies to patients globally. Previous Head of Clinical Development at Apellis where he successfully led the end-to-end clinical process for FDA approval of SYFOVRE. Ramiro Ribeiro, MD, PhD CMO

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Note: Dr. Modi and Dr. Regillo are paid consultants to EyePoint and are being compensated for their time in connection with this event. R&D Day Speakers: KOL Guest Speakers Associate Professor of Vitreoretinal Surgery, Retinal Disease and Uveitis at New York University; Director of Teleretina Yasha S. Modi, MD Professor of Ophthalmology at Thomas Jefferson University; Chief of Retina Service at Wills Eye Hospital; Founder of Wills Eye Clinical Retina Research Unit in Philadelphia and Partner, Mid Atlantic Retina Carl D. Regillo, MD, FACS

R&D Day: Agenda (1/2) ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain. PRESENTATION SPEAKER Introductions Jay Duker, M.D. Company Overview Jay Duker, M.D. DURAVYU™ (vorolanib intravitreal insert) Overview Jay Duker, M.D. DURAVYU™: Phase 2 DAVIO 2 Clinical Results and Sub-Group Analyses Yasha S. Modi, M.D. DURAVYU™: Phase 2 DAVIO 2 12-Month Topline Results Carl D. Regillo, M.D.

R&D Day: Agenda (2/2) ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRESENTATION SPEAKER DURAVYU™: Pivotal Phase 3 Plans for Wet AMD Jay Duker, M.D. Ramiro Ribeiro, M.D., Ph.D. Early Pipeline Jay Duker, M.D. Key Opinion Leader Insights and Discussion Jay Duker, M.D. Carl D. Regillo, M.D. Yasha S. Modi, M.D. Q&A All Closing Remarks Jay Duker, M.D. Ramiro Ribeiro, M.D., Ph.D.

R&D Day: Agenda ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRESENTATION SPEAKER Introductions Jay Duker, M.D. Company Overview Jay Duker, M.D. DURAVYU™ (vorolanib intravitreal insert) Overview Jay Duker, M.D. DURAVYU™: Phase 2 DAVIO 2 Clinical Results and Sub-Group Analyses Yasha S. Modi, M.D. DURAVYU™: Phase 2 DAVIO 2 12-Month Topline Results Carl D. Regillo, M.D.

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 3 Clinical Stage Company Leveraging Proven Delivery Technology DURAVYU™ (vorolanib intravitreal insert) Multi-billion-dollar market opportunities Proprietary Durasert E™ drug delivery technology ~$280M of cash and investments1 No debt Phase 3 Asset Compelling Pipeline Strong Balance Sheet 1-Unaudited estimate for June 30, 2024 Proven Technology

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Pipeline Represents Potential Multi Billion-Dollar Product Opportunities wet AMD, wet age-related macular degeneration; EOP2, End of Phase 2; FPI, first patient in; NPDR, non-proliferative diabetic retinopathy; DME, diabetic macular edema; GA, geographic atrophy Durasert E™ Programs Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Next Milestone DURAVYU (EYP-1901) – vorolanib in Durasert E™ (tyrosine kinase inhibitor) Wet AMD NPDR DME EYP-2301 – razuprotafib in Durasert E™ (TIE-2 agonist) serious retinal diseases Complement inhibition GA First Phase 3 Trial 2H 2024 12-month data Q3 2024 Topline data in Q1 2025 Pre-clin tox and PK data Potential product candidate in 2024 trial underway non-clinical STATISTICALLY NON-INFERIOR TO SOC BIOLOGIC EFFECT AND CONTINUED FAVORABLE SAFETY FULLY ENROLLED

Bioerodible DURASERT E™ TECHNOLOGY Safe, Sustained-Release IVT Drug Delivery Delivered via a standard in-office IVT injection Continuous, daily therapeutic dose Zero-order kinetics drug release Durasert E™: bioerodible Drug embedded within a bioerodible matrix as a solid insert Designed to deplete drug load before matrix fully erodes DURAVYU™ ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 12 IVT, intravitreal 1- licensed to Alimera; 2 – licensed to Bausch and Lomb

DURAVYU entering Phase 3 with robust dataset and FDA alignment on approval pathway ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. FDA, Food and Drug Administration; SAE, serious adverse event; MOA, mechanism of action No ocular or systemic DURAVYU-related SAEs across clinical trials SAFETY Non-inferiority pathway to approval aligned with FDA Most robust dataset of all long-acting treatments in development Phase 3 trial design includes re-dosing - aligns with FDA and clinical use Patented molecule with new MOA and best-in-class delivery technology FDA DATA TRIAL DESIGN NOVEL

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Vorolanib is a Potent and Highly Selective Pan-VEGF Receptor Inhibitor Sophie Bakri, M.D., et al. PLOS ONE, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0304782, 2024. VEGF(R), vascular endothelial growth factor (receptor); TKI, tyrosine kinase inhibitor; PDGF(R), platelet-derived growth factor (receptor); TIE-2, tyrosine-protein kinase receptor Best-in-class TKI Composition of matter patent into 2037 Demonstrated neuroprotection Potential antifibrotic Does not inhibit TIE-21 VEGFB VEGFA VEGFC VEGFD VEGFR1 VEGFR2 VEGFR3 TIE2 PDGFR ANG1 ANG2 PDGF Angiogenesis, permeability, leakage, growth, migration, and proliferation Blood vessel stability Endothelial cell Proliferation, motility Pericyte VOROLANIB PLGF

Vorolanib Demonstrated Compelling Clinical Activity in wet AMD Delivered Orally ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 16 Reduced supplemental therapy versus anti-VEGF PRN for all doses No ocular toxicity Systemic use significantly reduced fellow eye conversion Meaningful reduction in mean OCT thickness in treatment-naive patients Timothy L. Jackson, PhD, FRCOphth, et al. Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration. JAMAOphthalmology 2017.

DURAVYU: Vorolanib in Bioerodible Durasert E™ ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 17 Immediately bioavailable Controlled release for at least six months enables redosing regimen No free-floating drug - fully eluted prior to bioerosion of matrix Routine intravitreal injection Shipped and stored at ambient temperature Insert is ~1/5000 of vitreous volume and >90% drug

DURAVYU Demonstrated Clinically Meaningful Safety and Efficacy Outcomes Across Multiple Indications ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 18 Interim, masked safety as of June 2024 Wet AMD, wet age-related macular degeneration; NPDR, non-proliferative diabetic retinopathy; DME, diabetic macular edema Trial n size Indication Safety Key Efficacy Outcomes DAVIO 17 wet AMD Favorable safety profile No DURAVYU related ocular or systemic SAEs Stable BCVA and OCT 74% reduction in treatment burden DAVIO 2 161 wet AMD Statistically non-inferior BCVA >80% reduction in treatment burden Stable OCT PAVIA 77 NPDR Stable to improved disease severity up to 9-months; trial continuing 12 months VERONA 27 DME Trial underway DURAVYU Has Been Tested in 191 Patients to Date Across Different Indications

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. There is a Significant Need for More Durable Therapies in Wet AMD Many patients with wet AMD are chronically undertreated >80% of Retina Specialists say undertreatment is due to patient noncompliance, scheduling limitations or provider preference for less frequent dosing1 2 Current “treat and extend” protocol still places significant burden on physicians and patients Chronic disease treated with short acting anti-VEGF biologics A delay in care/missed visit can result in vision loss A delay in treatment of only 5.34 weeks resulted in vision loss2 3 1 4 An aging population means significantly more injections in a patient’s lifetime Current anti-VEGF treatments are dosed on average every two months in the United States3 1. 2022 PAT Survey; 2. American Academy of Ophthalmology, The Effect of Delay in Care Among Patients Requiring Intravitreal Injections, Welin Song, BS et al; 3. NIH Current and Upcoming Anti-VEGF Therapies and Dosing Strategies for the treatment of neovascular AMD: a comparative review, Saira Khanna et al, Dec. 2019

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DAVIO 2 Clinical Trial is Randomized, Double-Masked, Aflibercept Controlled* with a Single DURAVYU Treatment at Two Doses *Aflibercept on-label control required by FDA -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 DURAVYU 2mg low dose n=53 DURAVYU 3mg high dose n=54 Aflibercept 2mg q8W n=54 RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULED DURAVYU DOSE AFLIBERCEPT q8W DURAVYU/AFLIBERCEPT 1⁰ ENDPOINT BLEND W28 AND W32; UNMASK W32 SHAM INJECTION FOR MASKING Supplemental anti-VEGF injection based on pre-specified criteria

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control (95% CI) 1 – AAO 2022 presentation, Paolo Lanzetta, on behalf of the PULSAR study investigators DURAVYU 2mg -0.3* Mean Change in BCVA vs Aflibercept DURAVYU 3mg -0.4* +0.9* +1.0* +1.3* MEAN CHANGE IN BCVA FROM BASELINE In the Pulsar trial, HD Eylea (16-week 8mg arm) change in BCVA vs. 2mg Eylea was -1.4 letters1 *Blended week 28 and week 32 change vs. baseline **Month 8 represents 6 months after DURAVYU injection CI, Confidence Interval PRELIMINARY DATA – PENDING FINAL ANALYSIS

Clinically Meaningful Reduction in Treatment Burden Retrospectively Supports DURAVYU as a Maintenance Treatment For Wet AMD ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU 2mg DURAVYU 3mg Mean number of injections week 8 through week 32 0.55 0.73 Mean number of injections 6 months prior to screening* 4.98 5.02 Reduction in treatment burden vs. 6 months prior (%) 89% 85% *Normalized PRELIMINARY DATA – PENDING FINAL ANALYSIS

DURAVYU Demonstrated a Meaningful Reduction in Treatment Burden Prospectively vs. the Aflibercept Control Arm ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU 2mg DURAVYU 3mg Aflibercept 2mg q8W Mean number of injections week 8 through week 32 0.55 0.73 3.28 Reduction in treatment burden vs. aflibercept control (%) 83% 78% NA

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Nearly Two-Thirds of Eyes Treated with DURAVYU were Supplement-Free up to Six Months Summary of Supplement-Free Rates by Month 100% 100% *First visit patients are eligible to be supplemented EOM, every-other-month PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU/ Aflibercept Aflibercept Aflibercept Aflibercept Despite EOM aflibercept injections, 6% of the control group required additional supplementation

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU 2mg Dose Reduced Treatment Burden by 89% Compared to Prior 6 Months Injections in year prior and during the DAVIO 2 trial DURAVYU 3 mg (n = 52) DURAVYU 2 mg (n = 50) Anti-VEGF injection Aflibercept loading dose Aflibercept + DURAVYU No injection Missed Visit Supplemental injection

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS Injections in year prior and during DAVIO 2 trial DURAVYU 3 mg (n = 52) DURAVYU 2 mg (n = 50) Anti-VEGF injection Aflibercept loading dose Aflibercept + DURAVYU No injection Missed Visit Supplemental injection DURAVYU 3mg Dose Reduced Treatment Burden by 85% Compared to Prior 6 Months

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data from DAVIO 2 Suggests Strong Anatomic Control at 6-Months Compared to the Aflibercept Control **Month 8 represents 6 months after first DURAVYU injection PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU 2mg +12.4 Mean Change in CST vs Aflibercept DURAVYU 3mg +5.2 +10.6 um +17.8 um +5.4 um MEAN CHANGE in CST

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DAVIO 2 Case Study: Patient with Frequent Anti-VEGF Injections Was Maintained for at Least Six Months After Receiving DURAVYU = administration of DURAVYU (3mg) = administration of aflibercept Screening Week 12 Week 24 Day 1 Week 16 Week 28 Week 4 Week 20 Week 32 Week 8 BCVA 70 CST 217 BCVA 74 CST 219 BCVA 73 CST 216 BCVA 70 CST 236 BCVA 74 CST 218 BCVA 72 CST 214 BCVA 73 CST 218 BCVA 73 CST 216 BCVA 72 CST 214 BCVA 73 CST 216 BCVA, best-corrected visual acuity; CST, central subfield thickness. Anti-VEGF Injections Before and After Treatment Aflibercept + DURAVYU (3mg) Anti-VEGF injection Aflibercept + DURAVYU No injection Supplemental injection Aflibercept loading dose Missed Visit Last Visit Weeks -48 -44 -40 -36 -32 -28 -24 -20 -16 -12 -8 -4 0 4 8 12 16 20 24 28 32

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DAVIO 2 Case Study: Patient Treated with DURAVYU had Fluctuations in Fluid without Impact on Vision BCVA, best-corrected visual acuity; CST, central subfield thickness. = administration of DURAVYU (3mg) = administration of aflibercept Screening Week 12 Week 24 Day 1 Week 16 Week 28 Week 4 Week 20 Week 32 Week 8 BCVA 72 CST 211 BCVA 72 CST 213 BCVA 70 CST 269 BCVA 65 CST 234 BCVA 70 CST 223 BCVA 71 CST 242 BCVA 69 CST 237 BCVA 72 CST 258 BCVA 69 CST 227 BCVA 68 CST 219 Anti-VEGF Injections Before and After Treatment Aflibercept + DURAVYU (3mg) Anti-VEGF injection Aflibercept + DURAVYU No injection Supplemental injection Aflibercept loading dose Missed Visit Last Visit Weeks -48 -44 -40 -36 -32 -28 -24 -20 -16 -12 -8 -4 0 4 8 12 16 20 24 28 32

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DAVIO 2 Case Study: Patient Treated with DURAVYU Remained Dry with Only One Supplemental Injection BCVA, best-corrected visual acuity; CST, central subfield thickness. Week 28 Week 32 = administration of DURAVYU (2mg) = administration of aflibercept loading dose Screening Week 24 Day 1 Week 4 Week 8 BCVA 70 CST 246 BCVA 71 CST 289 BCVA 76 CST 233 Week 12 BCVA 68 CST 237 BCVA 70 CST 231 BCVA 76 CST 235 Week 16 BCVA 69 CST 435 BCVA 79 CST 236 Week 20 BCVA 68 CST 216 BCVA 75 CST 236 Anti-VEGF Injections Before and After Treatment Aflibercept + DURAVYU (2mg) Anti-VEGF injection Aflibercept + DURAVYU No injection Supplemental injection Aflibercept loading dose Missed Visit Last Visit Weeks -48 -44 -40 -36 -32 -28 -24 -20 -16 -12 -8 -4 0 4 8 12 16 20 24 28 32 = administration of aflibercept supplemental injection Criterion met

DURAVYU Phase 2 DAVIO 2 Clinical Trial in Wet AMD Met All Primary and Secondary Endpoints ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. . As of June 14, 2024 data cut PRELIMINARY DATA – PENDING FINAL ANALYSIS Endpoint 2mg 3mg R Primary: Non-inferior change in BCVA vs. aflibercept - 0.3 letters - 0.4 letters R Secondary: Favorable safety profile1 No DURAVYU-related SAEs R Secondary: Reduction in treatment burden vs. 6 mos prior 89% 85% R Secondary: Reduction in treatment burden vs. aflibercept 83% 78% R Secondary: Supplement-free up to 6 months 63% 88% of eyes had 0 or only 1 supplemental injections 63% 83% of eyes had 0 or only 1 supplemental injections R Secondary: Anatomical control vs. aflibercept +12.4um +5.2um

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Sub-Group Analysis of Supplement-Free Patients Demonstrated Eyes Treated with DURAVYU had Numerically Better Visual Acuity vs. Control *Blended week 28 and week 32 change vs. baseline **Month 8 represents 6 months after DURAVYU injection PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU 2mg +0.6* Mean Change in BCVA vs Aflibercept DURAVYU 3mg +0.1* +1.9* +2.3* +1.7* Sub-Group Analysis of Patients Supplement-Free Up to Six Months MEAN CHANGE IN BCVA FROM BASELINE

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Sub-Group Analysis of Supplement-Free Patients Demonstrated Strong Anatomic Control Up to 6-Months Compared to the Aflibercept Control *Month 8 represents 6 months after DURAVYU injection PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU 2mg +2.6 Mean Change in CST vs Aflibercept DURAVYU 3mg +0.6 +8.6 um +10.6 um +8.0 um Sub-Group Analysis of Patients Supplement-Free Up to Six Months MEAN CHANGE in CST

DURAVYU 2mg +0.4 Mean Change in BCVA vs Aflibercept DURAVYU 3mg +0.0 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. -0.5 -0.1 -0.5 Nearly Identical BCVA Compared to Aflibercept Through 12-Months After a Single Injection; Statistically Significant (95% CI) MEAN CHANGE IN BCVA FROM BASELINE PRELIMINARY DATA – PENDING FINAL ANALYSIS

©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Clinically Meaningful Supplement-Free Rates in DURAVYU Treated Eyes After Single Injection Summary of Supplement-Free Rates by Month 100% *First visit patients are eligible to be supplemented EOM, every-other-month PRELIMINARY DATA – PENDING FINAL ANALYSIS 100% 100% Aflibercept Aflibercept Aflibercept Aflibercept Aflibercept DURAVYU/ Aflibercept Despite EOM aflibercept injections, 22% of the control group required additional supplementation

DURAVYU 2mg +10.0 Mean Change in CST vs Aflibercept DURAVYU 3mg -0.1 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. +10.2 um +21.2 um +11.1 um PRELIMINARY DATA – PENDING FINAL ANALYSIS Data from DAVIO 2 Demonstrates Strong Anatomic Control in Eyes Treated with DURAVYU without Saw-Toothing Seen in Aflibercept Arm MEAN CHANGE in CST

DURAVYU Demonstrated a Favorable Safety Profile in the Phase 2 DAVIO 2 Clinical Trial No DURAVYU-related ocular or systemic SAEs No insert migration into the anterior chamber No retinal occlusive vasculitis Low patient discontinuation rate No discontinuations were related to DURAVYU treatment 1. As deemed by the investigator Data as of June 14, 2024 SAE, serious adverse event; AE, adverse event; IVT, intravitreal injection PRELIMINARY DATA CUT– PENDING FINAL ANALYSIS

Topline 12-Month DAVIO 2 Data Underscores Highly Positive Results ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 41 Efficacy: After a single injection, eyes treated with DURAVYU maintained stable visual acuity with strong anatomical control Approximately half of DURAVYU-treated eyes were supplement-free up to 12 months Safety: No ocular or systemic DURAVYU-related SAEs

R&D Day: Agenda ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRESENTATION SPEAKER DURAVYU™: Pivotal Phase 3 Plans for Wet AMD Jay Duker, M.D. Ramiro Ribeiro, M.D., Ph.D. Early Pipeline Jay Duker, M.D. Key Opinion Leader Insights and Discussion Jay Duker, M.D. Carl D. Regillo, M.D. Yasha S. Modi, M.D. Q&A All Closing Remarks Jay Duker, M.D.

Clear Regulatory Pathway for Phase 3 Pivotal Trials in wet AMD Informed by Multiple FDA Interactions ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 4Q 2022 Type C meeting to discuss pivotal trial design 4Q 2022 Received written FDA agreement on key trial design elements 3Q 2023 Initiated DAVIO 2 trial – design informed by Type C meeting to support future pivotals 4Q 2023 Positive DAVIO 2 data 2Q 2024 Positive EOP2 meeting with FDA 2Q 2024 Received EOP2 meeting minutes substantiating pivotal trial design 2H 2024 Initiate Phase 3 program – LUGANO (US) and LUCIA (US/Ex-US) to follow

Phase 3 Trials are Designed to Enable Global Regulatory Approval of DURAVYU ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Demonstrate DURAVYU, when administered every six months, achieves similar visual outcomes to on-label aflibercept while reducing treatment burden Two pivotal, non-inferiority trials ~400 patients per trial Two arms: 2.7mg DURAVYU vs. aflibercept control Primary Endpoint: difference in mean change in BCVA from Day 1 to Week 52 and 56 (blended) versus aflibercept control Secondary endpoints: safety, reduction in treatment burden, percent of eyes supplement-free, anatomical stability LUGANO/LUCIA: global, randomized, double-masked, aflibercept controlled Objective Design Endpoints

Phase 3 Program is Designed to Drive Global Regulatory and Commercial Success ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Only sustained release wet AMD program to evaluate reinjection for label Trials will enroll patients with active wet AMD (previously treated and treatment naïve) All patients will receive three loading doses of aflibercept Sham injections will be used for masking Primary efficacy endpoint at 12 months (basis for NDA submission) Safety will be monitored for 24 months Key trial design elements On track to be first sustained release wet AMD program with two pivotal trials to enable NDA submission to the FDA

DURAVYU in Wet AMD Phase 3 Pivotal Trial Design ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Screening D1 W4 W8 W12 W16 W24 W32 W84-W92 W20 W28 DURAVYU 2.7mg Aflibercept 2mg q8W RANDOMIZATION REQUIRED AFLIBERCEPT INJECTION VISIT VISIT SCHEDULED DURAVYU DOSE AFLIBERCEPT q8W 1⁰ ENDPOINT BLEND W52 AND W56; UNMASK W56 SHAM INJECTION FOR MASKING W36 W40 W44 W48 W52 W56 W60-W76 W80 W96 EOS AFLIBERCEPT Q8W Sham injection to mask for aflibercept injection Supplemental anti-VEGF injection based on pre-specified criteria AFLIBERCEPT load DURAVYU DURAVYU DURAVYU DURAVYU

A Broad Patient Population in the Phase 3 Pivotal Trials has the Potential to Enhance Trial Outcomes and Increase Commercial Opportunity ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Enriches trial to have more supplement-free eyes, which had better outcomes in DAVIO 2 Ensures broad label and global reimbursement Speeds enrollment; >80 sites already selected Supports real-world clinical use for physicians and patients Three loading doses of aflibercept; all patients will be previously treated when receiving DURAVYU

A Broad Patient Population in the Phase 3 Pivotal Trials has the Potential to Enhance Trial Outcomes and Increase Commercial Opportunity ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Patients diagnosed ≤1 year with ≤2 prior αVEGF injections Highly positive, statistically non-inferior DAVIO 2 results despite tough to treat population Average of 10 injections per year prior to enrollment Aflibercept arm (q8w) had nearly 25% supplementation rate despite receiving on-label injections Supplement-free eyes did the best visually and, in those eyes, DURAVYU performed numerically better than aflibercept visually In DAVIO 2, eyes that were pseudo naïve1 had fewer supplements than the overall cohort We believe the inclusion of treatment naive patients not only expands the potential patient population but also increases the probability of success

Commercial Manufacturing Facility ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. FDA, Federal Drug Administration; EMA, European Medicines Agency Conveniently located in Northbridge, MA, near EyePoint headquarters Built to US FDA and EU EMA standards 40,000 sqft cGMP manufacturing facility Built to EYPT specifications with no capital investment required preserving cash New manufacturing site for clinical and commercial products

EYP-2301: Razuprotafib in Durasert E™ is a Patented TIE-2 Agonist as a Potential New MOA for Treating Serious Retinal Diseases ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Heier et al. Retina, 2021;41:1-19. and Joussen et al. Eye 2021; 35:1305-1316.; 2. Hammes, et. Al – Diabetes.2011 Jan 1; 3. Shen et al. JCI, 2014; 124:4564; 4. Campochiaro et al. Ophthalmology, 2016; 123:1722-1730 EYP-2301 targets vascular endothelial protein tyrosine phosphatase (VE-PTP) to promote TIE-2 activation and maintain vascular stability in the retina P P EYP-2301 Blood vessel lumen Intracellular space VE-PTP ANG2 Tie-2 activation combined with VEGF inhibition has the potential to enhance efficacy and extend durability1 of treatment Razuprotafib (f/k/a AKB-9778) delivered subcutaneously demonstrated preclinical and clinical proof of concept in posterior segment disease 2,3

Data from Clinical and Preclinical Studies will be Presented at Multiple Upcoming Meetings ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Medical Conference Data Timing ASRS New DAVIO 2 sub-group analyses July 2024 American Retina Forum Encore presentation of XX data August 2024 Retina Society Topline DAVIO 2 12-month data September 2024 EURetina DAVIO 2 sub-group analyses Topline DAVIO 2 12-month data September 2024 AAO DAVIO 2 12-month sub-group analyses October 2024 FloRetina TBD December 2024 Publications Link Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration Patel S, Storey P, Barakat M, et al. Ophthalmology Science. 2024 Apr 8:4(5) https://www.ophthalmologyscience.org/article/S2666-9145(24)00063-0/fulltext Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects Bakri S, Lynch J, Howard-Sparks M, et al. PLOS One. 2024 June 4 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0304782

DURAVYU entering Phase 3 with robust dataset and FDA alignment on approval pathway ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. FDA, Food and Drug Administration; SAE, serious adverse event; MOA, mechanism of action No ocular or systemic DURAVYU-related SAEs across clinical trials SAFETY Non-inferiority pathway to approval aligned with FDA Most robust dataset of all long-acting treatments in development Phase 3 trial design including re-dosing - aligns with FDA and clinical use Patented molecule with new MOA and best-in-class delivery technology FDA DATA TRIAL DESIGN NOVEL

EX-99.2

Exhibit 99.2

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 –

– Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical trial evaluating DURAVYU for the treatment of wet AMD reinforcespotential as a sustained six-month maintenance therapy –

– Phase 2 trial of DURAVYU in diabetic macular edema (DME) fully enrolled –

– EyePoint to webcast its R&D Day event today at 8:00 a.m. ET –

WATERTOWN, Mass., June 26, 2024 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced the Company will highlight clinical and regulatory developments for its lead pipeline program, DURAVYU™(vorolanib intravitreal insert), formerly known as EYP-1901, its Durasert E™ sustained drug delivery technology, and early-stage programs during EyePoint’s R&D Day today, Wednesday, June 26, 2024, from 8:00 a.m. to 9:30 a.m. ET.

“EyePoint continues to pioneer the development of sustained-release drug delivery treatments for serious retinal diseases with DURAVYU™, a potentially paradigm-shifting, best-in-class treatment for patients suffering from VEGF-mediated retinal diseases,” said Jay Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals. “We have a track record of strong execution, establishing the most robust dataset among sustained delivery TKI programs in wet age-related macular degeneration. We are excited to share the positive twelve-month DAVIO 2 clinical trial data for DURAVYU, as well as our Phase 3 clinical trial plans for wet age-related macular degeneration (wet AMD), with first patient dosing anticipated in the second half of this year. Importantly, our planned Phase 3 design includes redosing, consistent with expected commercial use. We believe DURAVYU and our earlier-stage programs, including EYP-2301, are potentially multi-billion-dollar product opportunities, and we remain laser focused on advancing our mission of improving patient vision with innovative treatment options.”

R&D Day will feature commentary from EyePoint’s management team as well as key opinion leader (KOL) guest speakers, Carl D. Regillo, M.D., FACS, Professor of Ophthalmology at Thomas Jefferson University, Chief of Retina Service at Wills Eye Hospital, Founder of Wills Eye Clinical Retina Research Unit in Philadelphia, and Partner at Mid Atlantic Retina and Yasha S. Modi, M.D., Associate Professor of Vitreoretinal Surgery, Retinal Disease and Uveitis at New York University and Director of Teleretina.

R&D Day Highlights:

•

Phase 3 plans for DURAVYUTM in wet AMD, including key design elements of the Phase 3 LUGANO and LUCIA pivotal trials

Alignment on pathway to approval with U.S. Food and Drug Administration (FDA) based on positive End of Phase 2 meeting for two non-inferiority trials, 6-month redosing of DURAVYU and sham for masking with a one-year endpoint.

Each trial is expected to enroll approximately 400 patients with active wet AMD, including previously treated and treatment naïve patients, randomly assigned to either a

Exhibit 99.2

2.7mg dose of DURAVYU or an on-label aflibercept control. All patients to receive three monthly loading doses of aflibercept prior to DURAVYU with randomization occurring on Day 1.

The LUGANO (US) trial remains on track to initiate in 2H 2024 with LUCIA (US/ex-US) to follow.

•

Positive twelve-month safety and efficacy data from the Phase 2 DAVIO 2 clinical trial evaluating DURAVYUTMfor the treatment of wet AMD

Favorable safety profile – No DURAVYU related ocular or systemic SAEs

Best corrected visual acuity (BCVA) – Statistically significant visual acuity outcomes with both DURAVYU arms change in visual acuity nearly identical to aflibercept control arm through 12 months after a single injection of DURAVYU

Central Subfield Thickness (CST) – Strong anatomical control through 12 months after a single injection of DURAVYU

Supplement Free – After a single injection of DURAVYU, approximately half of the treated study eyes were anti-VEGF supplement free, while 22% of the eyes in the aflibercept control arm were administered a supplement despite these control eyes receiving mandated bi-monthly injections through 12 months

•

The VERONA trial, a Phase 2 trial of DURAVYUTM in diabetic macular edema (DME) patients has completed enrollment with 27 patients assigned to one of two intravitreal doses of DURAVYU or an aflibercept control. To date, DURAVYU is well-tolerated with no reported drug-related ocular or systemic serious adverse events in this trial.

“We are very encouraged with the excellent safety and efficacy results from our Phase 2 DAVIO 2 trial. We believe there remains a significant opportunity for a safe and effective sustained delivery maintenance treatment in wet AMD, and we believe the DAVIO 2 trial data reinforces the potential for DURAVYU to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer," said Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer of EyePoint Pharmaceuticals. "We look forward to enrolling patients in the Phase 3 LUGANO clinical trial for DURAVYU in wet AMD later this year, and we believe that with these DAVIO 2 results and our real-world-based pivotal trial design in-hand, we are in an excellent position to advance this innovative therapy and improve the lives of patients suffering from serious retinal diseases."

R&D Day Webcast Information

To access the live conference call, please register at https://register.vevent.com/register/BI10e9bca3aca34595a46c9a0e08ef92da. A live webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.

About the Phase 2 DAVIO 2 and Phase 3 LUGANO and LUCIA Clinical Trials

DAVIO 2 is a randomized, controlled Phase 2 clinical trial of DURAVYUTM in previously treated patients with wet AMD. Originally designed to enroll 144 patients, the trial enrolled 160 patients in total due to strong investigator and patient interest. All enrolled patients were previously treated with a standard-of-care anti-VEGF therapy and were randomly assigned to one of two doses of DURAVYU (approximately 2 mg or 3 mg) or an aflibercept control. DURAVYU is delivered with a single intravitreal

Exhibit 99.2

injection in the physician's office, similar to current FDA approved anti-VEGF treatments. The primary non-inferiority efficacy endpoint is change in BCVA compared to the aflibercept control, approximately six-months after the DURAVYU injection. Secondary endpoints include safety, change in CST as measured by optical coherence tomography (OCT), the number of eyes that remain free of supplemental anti-VEGF injections, and number of aflibercept injections in each group. More information about the trial is available at clinicaltrials.gov (identifier: NCT05381948).

EyePoint anticipates that the first patient in the Phase 3 LUGANO clinical trial of DURAVYU for wet AMD will be dosed in 2H 2024 and the LUCIA trial to follow. The pivotal trials are expected to enroll approximately 400 patients with active wet AMD each, including both previously treated and treatment naïve patients, randomly assigned to 2.7mg of DURAVYU versus an on-label aflibercept control. DURAVYU is delivered with a single intravitreal injection in the physician's office, similar to current FDA approved anti-VEGF treatments. The primary efficacy endpoint of the LUGANO and LUCIA trials is non-inferiority to the aflibercept control, as measured by change in BCVA twelve-months after two DURAVYU injections that will be administered six-months apart. Secondary efficacy endpoints include change in CST as measured by OCT, time to first supplemental anti-VEGF, reduction in treatment burden and safety.

About DURAVYUTM

DURAVYUTM, previously known as EYP-1901, is being developed as a potential paradigm-altering treatment for patients suffering from VEGF-mediated retinal diseases. DURAVYU delivers vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) formulated in a solid bioerodible insert using EyePoint’s proprietary sustained-release Durasert E™ technology. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor inhibitor, inhibiting all VEGF receptors. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection and may have antifibrotic benefits. DURAVYU is shipped and stored at ambient temperature and is administered with a standard intravitreal injection in the physician's office. DURAVYU is also immediately bioavailable with zero-order release kinetics release for approximately nine months.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYUTM (previously known as EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™. Pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Exhibit 99.2

Forward Looking Statements

EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes statements about the sufficiency of our existing cash resources through topline data for Phase 3 clinical trials for EYP-1901 (DURAVYU™) in wet AMD; our expectations regarding the timing and clinical development of our product candidates, including DURAVYU and EYP-2301; the potential for DURAVYU as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME); the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals including potential U.S. Food and Drug Administration (FDA) regulatory approval of DURAVYU and EYP-2301; the success of current and future license agreements; our dependence on contract research organizations, and other outside vendors and service providers; the success of Durasert®as a drug delivery platform in FDA approved products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; the impact of general business and economic conditions; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors:
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@sternir.com

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com